Overview

Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
This pilot study is designed to determine the feasibility and safety of administering docetaxel at various dosing levels on a bi-weekly schedule in older men with hormone refractory prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Geriatric Oncology Consortium
Collaborator:
Sanofi
Treatments:
Docetaxel
Hormones